GSK180736A_RP-HPLC_24239_MedChemExpress
中西医结合护理对胰腺炎急性反应期的护理效果分析
中西医结合护理对胰腺炎急性反应期的护理效果分析陈丽娇① 【摘要】 目的：探讨中西医结合护理对胰腺炎急性反应期的护理效果。
方法：选择2021年6月—2022年6月于漳州市中医院接受治疗的80例胰腺炎急性反应期患者作为本次研究对象，按照随机数表法将其分为试验组和对照组，各40例。
对照组给予常规护理，试验组在对照组的基础上给予中西医结合护理。
比较两组的临床症状恢复时间、血清炎症因子[白细胞介素-6（IL-6）、白细胞介素-15（IL-15）、肿瘤坏死因子-α（TNF-α）]水平、肠道屏障功能[血清淀粉酶（AMS）、D-乳酸和二胺氧化酶（DAO）]及并发症发生率。
结果：试验组临床症状恢复时间显著早于对照组，差异有统计学意义（P<0.05）。
干预后，试验组IL-6、IL-15、TNF-α水平均显著低于对照组，差异有统计学意义（P<0.05）。
干预后，试验组AMS、D-乳酸、DAO水平均显著低于对照组，差异有统计学意义（P<0.05）。
试验组并发症发生率显著低于对照组，差异有统计学意义（P<0.05）。
结论：中西医结合护理应用于胰腺炎急性反应期患者能促进患者临床症状恢复、降低炎症反应，加强肠道屏障功能，降低并发症发生率。
【关键词】 中西医结合护理 胰腺炎 急性反应期 肠道屏障功能 doi：10.14033/ki.cfmr.2023.25.026 文献标识码 B 文章编号 1674-6805（2023）25-0105-05 Nursing Effect of Integrated Traditional Chinese and Western Medicine Nursing on Acute Response Period of Pancreatitis/CHEN Lijiao. //Chinese and Foreign Medical Research, 2023, 21(25): 105-109 [Abstract] Objective: To explore the nursing effect of integrated traditional Chinese and western medicine nursing on acute response period of pancreatitis. Method: A total of 80 acute response period of pancreatitis patients who received treatment at Zhangzhou Traditional Chinese Medicine Hospital from June 2021 to June 2022 were selected as the subjects of this study. They were randomly divided into experimental group and control group using a random number table method, with 40 patients in each group. The control group received routine nursing, while the experimental group received integrated traditional Chinese and western medicine nursing on the basis of the control group. The clinical symptom recovery time, serum inflammatory factors [interleukin-6 (IL-6), interleukin-15 (IL-15), tumor necrosis factor-α (TNF-α)] levels, intestinal barrier function [serum amylase (AMS), D-lactate, and diamine oxidase (DAO)] and incidence of complications between the two groups were compared. Result: The recovery time of clinical symptoms in the experimental group were significantly earlier than those in the control group, the differences were statistically significant (P<0.05). After intervention, the levels of IL-6, IL-15, TNF-α in the experimental groups were significantly lower than those in the control group, the differences were statistically significant (P<0.05). After intervention, the levels of AMS, D-lactate, and DAO in the experimental group were significantly lower than those in the control group, the differences were statistically significant (P<0.05). The incidence of complications in the experimental group was significantly lower than that in the control group, the differences were statistically significant (P<0.05). Conclusion: The application of integrated traditional Chinese and western medicine nursing in the acute response period of pancreatitis patients can accelerate the recovery of clinical symptoms, reduce inflammatory reactions, strengthen intestinal barrier function, and reduce the incidence of complications. [Key words] Integrated traditional Chinese and western medicine nursing Pancreatitis Acute response period Intestinal barrier function First-author's address: Zhangzhou Traditional Chinese Medicine Hospital, Zhangzhou 363000, China 胰腺炎是患者在酗酒、暴饮暴食、胆道系统疾病等诱因下发生胰腺组织微循环障碍的多发性消化系统疾病，临床主要表现为急性腹痛、高热、恶心呕吐等[1-2]。
能谱CT_冠状动脉血管成像对糖尿病患者合并冠状动脉病变的诊断价值研究
CHINA MEDICINE AND PHARMACY Vol.14 No.7 April 2024149能谱CT冠状动脉血管成像对糖尿病患者合并冠状动脉病变的诊断价值研究叶万春 张永婕 阮彩霞福建医科大学附属福州市第一医院放射科，福建福州 350009[摘要] 目的 能谱CT 冠状动脉血管成像（CCTA）对糖尿病患者合并冠状动脉病变的预测价值。
方法 选取2020年8月至2022年8月福建医科大学附属福州市第一医院收治的88例疑似2型糖尿病（T2DM）合并冠状动脉病变患者，共随机选取352个冠脉节段，均接受能谱CCTA 检查，以冠状动脉造影（CAG）为金标准，分析能谱CCTA 对T2DM 患者冠状动脉病变、冠脉狭窄程度及冠脉斑块类型的诊断效能。
结果 88例T2DM 患者能谱CCTA 诊断有56例合并冠状动脉病变，352个冠脉节段中，无狭窄134例，轻度狭窄115例，中度狭窄68例，重度狭窄10例，无斑块135例，钙化斑块26例，非钙化斑块103例，混合斑块67例。
能谱CCTA 诊断T2DM 患者冠状动脉病变的准确度为88.64%，Kappa 值为0.733；诊断冠脉轻度狭窄、中度狭窄、重度狭窄的准确度分别为95.74%、95.82%、97.73%，Kappa 值分为0.900、0.857、0.702；诊断冠脉钙化斑块、非钙化斑块、混合斑块的准确度分别为96.01%、97.43%、98.24%，Kappa 值分为0.754、0.964、0.969。
结论 能谱CCTA 诊断T2DM 患者冠状动脉病变、冠脉狭窄程度及冠脉斑块类型均具有较好的诊断效能，能为临床T2DM 合并冠状动脉病变早期诊断、治疗工作提供一定参考，值得推广。
[关键词] 能谱CT 冠状动脉血管成像；糖尿病；冠状动脉病变；冠状动脉造影；诊断价值[中图分类号] R541.4；R587.2 [文献标识码] A [文章编号] 2095-0616（2024）07-0149-05DOI:10.20116/j.issn2095-0616.2024.07.34Study on the diagnostic value of spectral coronary computedtomography angiography in diabetes patients with coronary artery diseaseYE Wanchun ZHANG Yongjie RUAN CaixiaDepartment of Radiology, the First Hospital of Fuzhou Affiliated to Fujian Medical University, Fujian, Fuzhou 350009, China [Abstract] Objective To explore the diagnostic value of spectral coronary computed tomography angiography (CCTA) in diabetes patients with coronary artery disease. Methods A total of 88 patients with suspected type 2 diabetes mellitus (T2DM) complicated with coronary artery disease admitted to The First Hospital of Fuzhou affiliated to Fujian Medical University from August 2020 to August 2022 were selected. A total of 352 coronary segments were randomly selected and examined by spectral CCTA. Coronary angiography (CAG) was used as the gold standard to analyze the diagnostic efficacy of spectral CCTA on the severity of coronary artery disease, degree of coronary stenosis, and type of coronary plaques for T2DM patients. Results Among the 88 T2DM patients diagnosed by spectral CCTA, 56 cases were complicated with coronary artery disease. Among 352 coronary segments, 134 had no stenosis, 115 had mild stenosis, 68 had moderate stenosis, 10 had severe stenosis, 135 had no plaque, 26 had calcified plaques, 103 had noncalcified plaques, and 67 had mixed plaques. The accuracy of spectral CCTA in diagnosing coronary artery disease in T2DM patients was 88.64%, and the Kappa value was 0.733. The accuracies for diagnosing mild, moderate, and severe coronary stenosis were 95.74%, 95.82%, and 97.73%, respectively. The corresponding Kappa values were 0.900, 0.857, and 0.702. The accuracies for diagnosing coronary calcified plaques, noncalcified plaques, and mixed plaques were 96.01%, 97.43%, and 98.24%, respectively. The corresponding Kappa values were 0.754, 0.964, and 0.969. Conclusion Spectral CCTA has good diagnostic efficacy in diagnosing the severity of coronary artery disease, degree of coronary stenosis, and type of coronary plaques in T2DM patients. It can provide some reference for early diagnosis and treatment of T2DM combined with coronary artery disease in clinical practice and is worth promoting.[Key words] Spectral coronary computed tomography angiography; Diabetes mellitus; Coronary artery disease; Coronary angiography; Diagnostic valueCHINA MEDICINE AND PHARMACY Vol.14 No.7 April 2024150据统计，2017年全球高达4.51亿人患有糖尿病，预计2045年全球糖尿病人数将超6.93亿人[1]。
糖尿病患者诊断应用血清C肽及糖化血红蛋白联合检测的价值分析
DOI：10.16658/ki.1672-4062.2023.14.085糖尿病患者诊断应用血清C肽及糖化血红蛋白联合检测的价值分析倪胜南，陈少，陈一鸣泗阳康达医院检验科，江苏宿迁223700[摘要]目的探讨糖尿病患者诊断应用血清C肽联合糖化血红蛋白检测的价值。
方法将2022年1月—2023年1月泗阳康达医院收治的74例疑似糖尿病患者作为研究对象，检测入组患者糖化血红蛋白（glycosylated hemoglobin, HbA1c）以及血清C肽水平，以口服葡萄糖耐量试验（glucose tolerance test check, OGTT）为金标准，统计血清C肽联合糖化血红蛋白检测与单一项目检测的敏感性、特异度和诊断符合率。
结果74例疑似糖尿病患者根据葡萄糖耐量试验结果，确诊患者67例，确诊率为90.54%（67/74）；与血清C肽、HbA1c单一检测相比，血清C肽+HbA1c联合检测敏感度更高，差异有统计学意义（P<0.05）；血清C肽+HbA1c联合检测的特异度略高于血清C肽、HbA1c单一检测，但差异无统计学意义（P>0.05）；联合检测诊断符合率明显高于血清C 肽、HbA1c单项检测，差异有统计学意义（P<0.05）。
结论血清C肽与糖化血红蛋白是临床诊断糖尿病的重要参考指标，二者表达水平的变化有助于检测患者胰岛素分泌功能，评估疾病严重程度，两者联合检验灵敏性与特异度良好，有助于早期明确诊断，临床参考价值较高。
[关键词] 糖尿病；血清C肽；糖化血红蛋白；诊断价值[中图分类号] R446.1 [文献标识码] A [文章编号] 1672-4062（2023）07（b）-0085-04Analysis of the Value of the Diagnostic Application of Combined Serum C-peptide and Glycosylated Hemoglobin Testing in Patients with Diabetes MellitusNI Shengnan, CHEN Shao, CHEN YimingDepartment of Laboratory Medicine, Siyang Kangda Hospital, Suqian, Jiangsu Province, 223700 China[Abstract] Objective To explore the value of applying serum C-peptide combined with glycated hemoglobin test for the diagnosis of diabetic patients. Methods A total of 74 patients with suspected diabetes admitted to Siyang Kangda Hospital from January 2022 to January 2023 were selected as the research objects. The levels of glycosylated hemoglo‐bin (HbA1c) and serum C-peptide were detected. Oral glucose tolerance test (OGTT) was used as the gold standard. The sensitivity, specificity and diagnostic coincidence rate of serum C-peptide combined with glycosylated hemoglo‐bin detection and single item detection were statistically analyzed. Results According to the results of glucose toler‐ance test, 67 patients were diagnosed in 74 patients with suspected diabetes, and the diagnosis rate was 90.54% (67/ 74). Compared with the single detection of serum C-peptide and HbA1c, the sensitivity of combined detection of se‐rum C peptide and HbA1c was higher, and the difference was statistically significant (P<0.05). The specificity of com‐bined detection of serum C-peptide and HbA1c was slightly higher than that of single detection of serum C-peptide and HbA1c, but the difference was no statistically significant (P>0.05). The diagnostic coincidence rate of combined detection was significantly higher than that of single detection of serum C-peptide and HbA1c, and the difference was statistically significant (P<0.05). Conclusion Serum C-peptide and glycosylated hemoglobin are important reference indexes for clinical diagnosis of diabetes mellitus, and changes in the expression levels of the two can help to detect the insulin secretion function of patients and assess the severity of the disease. The sensitivity and specificity of the [作者简介]倪胜南（1991-），女，本科，主管检验师，研究方向为免疫学、分子生物学检验。
维持性血液透析对终末期肾病患者的治疗及临床预后评价
DOI：10.16662/ki.1674-0742.2023.29.052维持性血液透析对终末期肾病患者的治疗及临床预后评价王迎春，杨文杰，张智成仙游博爱医院，福建莆田351200［摘要］目的分析终末期肾病患者接受维持性血液透析的治疗效果、临床预后。
方法随机选取2021年1—12月仙游博爱医院收治的80例终末期肾病患者为研究对象，应用随机数表法分为对照组和观察组，包括对照组40例和观察组40例，均接受维持性血液透析治疗，对照组使用低通量血液透析，观察组使用高通量血液透析。
对比两组疗效及预后。
结果观察组临床总疗效（95.00%）高于对照组（77.50%），差异有统计学意义（χ2=5.164，P<0.05）。
两组血肌酐、尿素氮对比，差异无统计学意义（P>0.05）。
治疗后，观察组血清甲状旁腺激素、β2-微球蛋白水平低于对照组，差异有统计学意义（P<0.05）。
两组血钙水平比较，差异无统计学意义（P>0.05）。
治疗后，观察组血磷水平低于对照组，差异有统计学意义（P<0.05）。
观察组并发症发生率为7.50%，低于对照组，差异有统计学意义（χ2=4.500，P<0.05）。
结论应用维持性血液透析治疗终末期肾病患者的临床疗效良好，特别是与低通量血液透析相比，采取高通量血液透析的治疗方式，可以显著提升患者临床预后，改善各种临床指标，降低并发症发生率。
［关键词］终末期肾病；维持性血液透析；临床疗效；钙磷代谢水平；并发症［中图分类号］R5 ［文献标识码］A ［文章编号］1674-0742（2023）10(b)-0052-04Evaluation of the Treatment and Clinical Prognosis of Patients with End-stage Renal Disease by Maintenance HemodialysisWANG Yingchun, YANG Wenjie, ZHANG ZhichengXianyou Boai Hospital, Putian, Fujian Province, 351200 China[Abstract] Objective To analyze the therapeutic effect and clinical prognosis of patients with end-stage renal disease receiving maintenance hemodialysis. Methods A total of 80 patients with end-stage renal disease admitted to Xianyou Boai Hospital from January 2021 to December 2021 were randomly selected as the study objects and divided into con⁃trol group and observation group by random number table method, including 40 cases in the control group and 40 cases in the observation group, all of whom received maintenance hemodialysis treatment. The control group received low-flux hemodialysis, and the observation group received high-flux hemodialysis. The efficacy and prognosis of the two groups were compared. Results The total clinical efficacy of observation group (95.00%) was higher than that of control group (77.50%), and the difference was statistically significant (χ2=5.164, P<0.05). There was no statistically significant difference in serum creatinine and urea nitrogen between two groups after treatment (P>0.05). After treat⁃ment, the serum parathyroid hormone and β2-microglobulin levels in observation group were lower than those in con⁃trol group, and the difference was statistically significant (P<0.05). There was no statistically significant difference in blood calcium level between two groups (P>0.05), After treatment, the blood phosphorus level of the observation group was lower than that of the control group, and the difference was statistically significant (P<0.05). The complication rate of observation group was 7.50%, which was lower than that of control group, and the difference was statistically signifi⁃cant (χ2=4.500, P<0.05). Conclusion The application of maintenance hemodialysis in the treatment of end-stage renal disease patients has good clinical efficacy, especially compared with low-flux hemodialysis, the adoption of high-flux [作者简介] 王迎春（1981-），女，本科，主治医生，研究方向为血液透析。
孕晚期B族链球菌阴道直肠定植产妇分娩后新生儿的早期干预效果分析
论著China &Foreign Medical Treatment 中外医疗孕晚期B 族链球菌阴道直肠定植产妇分娩后新生儿的早期干预效果分析李小艳，杨晓明徐州仁慈医院产科，江苏徐州 221000［摘要］ 目的 探讨孕晚期B 族链球菌（group B streptococcus, GBS ）阴道直肠定植产妇分娩后新生儿早期干预效果分析。
方法 随机选取2021年4月—2023年4月徐州仁慈医院妇产科孕龄>32周的100例GBS 筛检阳性孕妇分娩后的新生儿，以随机数表法分为研究组与对照组，研究组新生儿娩出后立即予以阿莫西林颗粒口服，对照组未进行早期干预。
比较两组血细胞数、CRP 和PCT 水平，以及新生儿GBS 感染情况。
结果 出生当日，两组PCT 水平比较，差异有统计学意义（P <0.05）；两组血细胞数、CRP 水平比较，差异无统计学意义（P >0.05）。
出生次日和第7日，研究组血细胞数、CRP 和PCT 水平低于对照组，差异有统计学意义（P <0.05）。
共检出20例GBS 感染，研究组早发性GBS 疾病2例，无迟发性GBS 疾病，对照组早发性GBS 疾病11例，迟发性GBS 疾病7例。
研究组GBS 感染发生率低于对照组，差异有统计学意义（P <0.05）。
结论 适当的早期干预可显著降低新生儿GBS 感染。
［关键词］ B 族链球菌；感染；干预；效果分析［中图分类号］ R722 ［文献标识码］ A ［文章编号］ 1674-0742（2023）07(a)-0037-04Analysis of Early Intervention Effect of Neonates in Women with Group B Streptococcus Vaginorectal Colonization in Late Pregnancy after DeliveryLI Xiaoyan, YANG XiaomingDepartment of Obstetrics, Xuzhou Renci Hospital, Xuzhou, Jiangsu Province, 221000 China[Abstract] Objective To explore the effectiveness of early intervention for newborns after vaginal rectal colonization of group B streptococcus (GBS) in late pregnancy. Methods From April 2021 to April 2023, 100 newborns of GBS screening positive pregnant women with gestational age>32 weeks in the obstetrics and gynecology department of Xu⁃zhou Renci Hospital were randomly selected and divided into the study group and the control group by random num⁃ber table. The study group newborns were given Amoxicillin granules orally immediately after delivery, while the con⁃trol group did not receive early intervention. Compared the blood cell count, CRP and PCT levels, as well as the inci⁃dence of neonatal GBS infection between the two groups. Results On the day of birth, there was a statistically signifi⁃cant difference in PCT levels between the two groups (P <0.05); there was no statistically significant difference inblood cell count and CRP levels between the two groups (P >0.05). On the day after birth and the 7th day, the blood cell count, CRP, and PCT levels in the study group were lower than those in the control group, and the difference was statistically significant (P <0.05). A total of 20 cases of GBS infection were detected, with 2 cases of early onset GBS disease and no late onset GBS disease in the study group. There were 11 cases of early onset GBS disease and 7 casesof late onset GBS disease in the control group. The incidence of GBS infection in the study group was lower than that in the control group, and the difference was statistically significant (P <0.05). Conclusion Appropriate early interven⁃tion can significantly reduce GBS infection in newborns.DOI ：10.16662/ki.1674-0742.2023.19.037[基金项目] 徐州仁慈医院集团科技创新课题非限制类技术（XZRCKY-KT-202204007）。
高效液相色谱法和酶放大免疫法检测伏立康唑血药浓度相关性分析
高效液相色谱法和酶放大免疫法检测伏立康唑血药浓度相关性分析李俊明;卓思珺;陈仕鹏;刘成裕;谢瑞杰【期刊名称】《中国药业》【年(卷),期】2022(31)22【摘要】目的探讨高效液相色谱(HPLC)法和酶放大免疫(EMIT)法测定人血清伏立康唑(VRC)质量浓度的相关性。
方法收集医院2019年至2020年住院和门诊患者常规VRC检测样本2045份,对其中59份样本同时采用两种检测方法,并采用双侧配对t检验分析结果的相关性;建立回归方程并绘制Bland-Altman图;按质量浓度结果分为A组(<1.0µg/mL)、B组(1.0~5.5µg/mL)和C组(>5.5µg/mL),采用Wilcoxon检验、Passing-Bablok线性回归和Bland Altman法分析3组的相关性及一致性。
分析2045份样本血药浓度测定结果。
结果两种测定方法具有高度相关性(r=0.879,P<0.05);不同质量浓度下,两种测定方法一致性很差,EMIT法检测结果均高于HPLC法。
结论临床测定VRC血药浓度时,应关注不同检测方法的差异,相应调整临床用药剂量;HPLC法和EMIT法检测结果不具有直接比较意义。
【总页数】4页(P56-59)【作者】李俊明;卓思珺;陈仕鹏;刘成裕;谢瑞杰【作者单位】广西壮族自治区柳州市人民医院药学部【正文语种】中文【中图分类】R969.3;R978.19【相关文献】1.荧光偏振免疫分析法与高效液相色谱法检测环孢素A血药浓度的倒方差法Meta 分析2.酶放大免疫分析法与二维高效液相色谱法监测万古霉素血药浓度的比较3.酶放大免疫法与荧光偏振免疫法检测环孢素A血药浓度对比研究4.均相酶扩大免疫分析法与高效液相色谱法测定癫痫患儿丙戊酸钠血药浓度比较研究5.双波长高效液相色谱法同时检测环孢素A及伏立康唑血药浓度因版权原因，仅展示原文概要，查看原文内容请购买。
RP-HPLC法测定众生丸中芍药苷的含量
[ Abstra川 Objective To em ablieb . method for determination of paeoniflorin in Zhongsheng Pills 勿 RP-HPL Methods The column ， AD a-C ( 250 x 4.6 ma , 5 pr ) . M C. . tim n o ethanol- . 05 mol L phosphoric 0 /
作者单位:518026 裸圳市第二人民医院药荆科
2. 2 供试品溶液的制备 取众生丸样品， 除去糖 衣， 研细.精密称取约 1. 0 g， 加人甲醇25 ml ， 称重， 超声提取20 min ， 放冷， 称定重量， 用甲醇补足减失 重量， 摇匀， 滤过， 即得。 2. 3 对照品贮备溶液的制备 精密称取经五氧化 二磷减压干燥36 h 的芍药昔 10. 80 mg, 置 100 ml 容量瓶中.加甲醇溶解并稀释至刻度， 摇匀， 制得每 ml 含。108 mg 芍药昔的对照品 . 贮备溶液。 2. 4 空白样品溶液的制备 按处方依法制得缺赤 芍的 空白 样品溶液。分别精密吸取对照品溶液、 供 试品 溶液、 样品对照溶液各 10 闪注人液相色 空白 谱仪， 按上述色谱条件测定， 记录色谱图。结果表 明， 样品溶液在芍药昔对照品色谱峰相应的位 空白 置上， 无干扰峰。结果见图 1, 2. 5 精密度试验 取对照品贮备液按“ 1” 2. 项下 条件重复进样6 次， 测定峰面积， 测得芍药昔峰面积 RSD为0. 37%( n = 6) ， 表示仪器精密度良 好。 2. ‘ 重复性试验 精密取同一批号供试品(批号 040803)6 份， 按供试品溶液制备方法制备供试品溶 液， 2. 1” 按“ 项下条件， 测定峰面积。 结果6 份供试品 峰面积的RSD 为0. 96% 。表明该方法重复性良 好。 2. 7 稳定性试验 取众生丸样品( 批号 040803 ) 1. 0 g ， 精密称定， 按供试品溶液制备方法制备供试 品溶液， 2. 1” 按“ 项下条件， 分别于制备后 0,2 ,4 ,6 , 8, 12 h 测定峰面积。结果 RSD =0. 7296 ( n 二 ， 6) 表 明 12 h 内测定样品稳定。
高效液相色谱法测定硝酸咪康唑乳膏的含量
高效液相色谱法测定硝酸咪康唑乳膏的含量
吴月萍
【期刊名称】《海峡药学》
【年(卷),期】2013(025)010
【摘要】目的改进硝酸咪康唑乳膏含量测定检测的方法.方法 C18柱,柱温25℃;流动相:0.01mol·L-1醋酸铵-乙腈-甲醇(15:42.5:42.5);流速1.0mL·min-1;检测波长为230nm.以外标法计算含量.结果在0.380mg·mL-1～1.898mg·mL-1范围内线性良好,r=0.9997(n=5);回收率为99.6%(n=9,RSD=0.8%);重复性RSD为0.8%,最低检测限为1ng.结论本方法可用于硝酸咪康唑乳膏的含量测定,灵敏度高、准确可靠.
【总页数】3页(P81-83)
【作者】吴月萍
【作者单位】厦门大学附属第一医院思明分院药剂科,厦门,361003
【正文语种】中文
【中图分类】R927.2
【相关文献】
1.RP-HPLC法测定硝酸咪康唑乳膏含量内外标比较 [J], 郑淑凤
2.高效液相色谱-荧光法或超高效液相色谱-四极杆/轨道阱质谱法测定抑郁症小鼠海马中5-羟色胺和相关的2种物质含量的比较 [J], 王丽; 朱军; 环飞; 程洁; 吴倩
3.高效液相色谱法测定庆大霉素普鲁卡因维B12胶囊中维生素B12的含量及含量均匀度的评价 [J], 梁秋霞;陈瀚;黄丽丽;朱健萍;卢日刚
4.钩藤药材中异钩藤碱含量的超高效液相色谱和高效液相色谱法测定 [J], 李思蒙;侴桂新
5.高效液相色谱和超高效液相色谱法测定乳制品中三聚氰胺含量的对比 [J], 冯小丽
因版权原因，仅展示原文概要，查看原文内容请购买。
德谷门冬双胰岛素注射液治疗2_型糖尿病的疗效及安全性研究
DOI：10.16658/ki.1672-4062.2023.19.084德谷门冬双胰岛素注射液治疗2型糖尿病的疗效及安全性研究戴卉，张开凤，朱凤丽江苏省镇江市丹徒区人民医院内分泌科，江苏镇江212000[摘要]目的探讨德谷门冬双胰岛素注射液在2型糖尿病中的效果以及安全性。
方法选取2022年1月—2023年7月江苏省镇江市丹徒区人民医院收治的62例2型糖尿病患者为研究对象，按随机数表法分为对照组（n=31）和观察组（n=31）。
对照组患者接受门冬胰岛素30注射液治疗，观察组患者接受德谷门冬双胰岛素注射治疗。
对比两组患者临床疗效、血糖变化和不良反应发生率。
结果观察组治疗有效为96.77%，高于对照组的77.42%，差异有统计学意义（χ2=5.167，P=0.023）。
治疗前，两组患者血糖水平比较，差异无统计学意义（P>0.05）；治疗后，两组患者血糖水平均改善，且观察组血糖指标低于对照组，差异有统计学意义（P< 0.05）。
观察组不良反应发生率低与对照组，差异有统计学意义（P<0.05）。
结论德谷门冬双胰岛素的应用可以明显改善2型糖尿病患者血糖水平，疗效更为确切，且安全性更高，不会增加用药后不良反应。
[关键词] 2型糖尿病；德谷门冬双胰岛素；门冬胰岛素30注射液；安全性[中图分类号] R587 [文献标识码] A [文章编号] 1672-4062（2023）10（a）-0084-04Study on the Efficacy and Safety of Insulin Degludec and Insulin Aspart Injection in the Treatment of Type 2 Diabetes MellitusDAI Hui, ZHANG Kaifeng, ZHU FengliDepartment of Endocrinology, Zhenjiang Dantu District People's Hospital, Zhenjiang, Jiangsu Province, 212000 China [Abstract] Objective To explore the effect and safety of insulin degludec and insulin aspart injection in type 2 diabe⁃tes mellitus.Methods 62 patients of type 2 diabetes mellitus patients admitted to Zhenjiang Dantu District People's Hospital, Jiangsu Province from January 2022 to July 2023 were selected as study objects and divided into the control group (n=31) and the observation group (n=31) by taking the random number table method. The patients in the control group were treated with insulin aspart 30 injection and the patients in the observation group were treated with insulin degludec and insulin aspart injection. Compared the clinical efficacy, the changes in blood glucose and the incidence of adverse reactions between the two groups of patients.Results The treatment effectiveness of the observation group was 96.77%, which was higher than that of the control group, which was 77.42%, and the difference was statistically significant (χ2=5.167, P=0.023). There was no statistically significant difference in blood glucose levels between the two groups before treatment (P>0.05). After treatment, blood glucose levels improved in both groups, and the level of blood glucose in the observation group were lower than those in the control group, and the difference was statistically significant (P<0.05). The incidence of adverse reactions in the observation group was lower than that in the control group, and the difference was statistically significant (P<0.05).Conclusion The application of insulin degludec and in⁃sulin aspart can significantly improve the blood glucose level of patients with type 2 diabetes mellitus, the efficacy is more accurate, and the safety is higher, and it will not increase the occurrence of adverse reactions after the use of medication.[作者简介]戴卉（1985-），女，本科，主治医师，研究方向为内分泌科。
GSK180736A_SDS_MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:May-24-2017Print Date:May-24-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :GSK180736ACatalog No. :HY-18990CAS No. :817194-38-01.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:NoneFormula:C19H16FN5O2Molecular Weight:365.36CAS No. :817194-38-04. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance light yellow to khaki (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
RP-HPLC法测定复方蛇床子搽剂中蛇床子素和醋酸地塞米松含量及方法验证
RP-HPLC法测定复方蛇床子搽剂中蛇床子素和醋酸地塞米松含量及方法验证郑绍忠;王庆芬;张荣;黄艺蓉【摘要】建立复方蛇床予搽剂中蛇床子素和醋酸地塞米松含量的RIP-HPLC测定法.方法:色谱条件为色谱柱:Sino Chrom ODS-BP(4.6mm× 250mm,5pm);检测波长240nm;柱沮35℃;流动相:甲醇-水(7S:2S);进样:20μl(样品用乙醇稀释8倍):流速:0.8ml·min-1;分析时间:30min.结果:回归方程与相关性;蛇床子素(进样范嘲2.608～13.04μg,Y =850574.6X+120226A,r=0.9992,);醋酸地塞米松(进样范围0.1808～1.4464μg,Y=1748870X+249657,r=9996).加样回收率(n=3):蛇床子素98.65%,醋酸地塞米松98.0%.建立的方法用于供试制剂中蛇床子素和醋酸地塞米松的测定,简单,快速,准确,可行.【期刊名称】《漳州职业技术学院学报》【年(卷),期】2008(010)004【总页数】3页(P16-18)【关键词】RP-HPLC法;蛇床子素;醋酸地塞米松【作者】郑绍忠;王庆芬;张荣;黄艺蓉【作者单位】中国人民解放军第一七五医院,福建,漳州,363000;中国人民解放军第一七五医院,福建,漳州,363000;中国人民解放军第一七五医院,福建,漳州,363000;中国人民解放军第一七五医院,福建,漳州,363000【正文语种】中文【中图分类】R927.2复方蛇床子搽剂是由蛇床子、薄荷脑、醋酸地塞米松、丙酮、乙醇组成的外用液体制剂，具有清热解毒、燥湿祛风、消炎止痒作用。
临床用于各种瘙痒性皮肤病，如神经性皮炎、湿疹性皮炎等，取得满意的效果。
为有效地控制制剂质量，参考有关文献[1，2]，采用RP–HPLC法，以制剂成品中蛇床子素和醋酸地塞米松为指标，进行含量测定方法研究。
1.1 仪器高效液相色谱系统：Waters 510 高效液相泵，Waters TM717 自动进样器，Waters TM996 二极管阵列检测器，Waters 温度控制仪，Millennium 2010 色谱处理系统；超声波清洗机：北京天鹏新技术有限公司。
反相高效液相色谱法测定体液中哌拉西林浓度及其药代动力学研究
反相高效液相色谱法测定体液中哌拉西林浓度及其药代动力学研究褚志杰;李珍;唐世新;范国荣;计一平;胡晋红【期刊名称】《药学服务与研究》【年(卷),期】2002(2)3【摘要】目的 :建立测定体液中哌拉西林浓度的 HPLC法并应用于人体药代动力学研究。
方法 :8名志愿者单剂量静脉滴注 4g哌拉西林钠 ,采用 RP-HPL C法测定血浆和尿中药物浓度。
结果 :滴注完成即刻 cm ax为(2 0 3 .2 4± 44 .13 )μg/ml,t1 / 2β为(0 .76± 0 .0 9) h,分布容积 (Vc)为(2 0 .64± 4.67) L,清除率 (Cls)为 (2 4.86± 4.13 ) L/h,AUC为(2 15 .5 2±3 8.75 ) μg·h·ml-1。
结论 :哌拉西林的体内过程符合二室开放模型 ,主要以原形经肾脏排出体外 ,8h累积尿排百分率为(61.0 0± 5 .5 5 ) %。
【总页数】3页(P168-170)【关键词】哌拉西林;药代动力学;高压液相色谱法【作者】褚志杰;李珍;唐世新;范国荣;计一平;胡晋红【作者单位】武警山东总队医院药剂科;第二军医大学长海医院药学部【正文语种】中文【中图分类】R978.11【相关文献】1.反相高效液相色谱法测定兔血清中拉莫三嗪的浓度及其动物药代动力学研究 [J], 胡永狮;吴平;汤秋华2.在线柱切换反相高效液相色谱法测定大鼠血浆丁螺环酮浓度及药代动力学研究[J], 张晓惠;王荣;谢华;尹强;李晓云;贾正平;张娟红;李文斌3.在线柱切换反相高效液相色谱法测定大鼠血浆丁螺环酮浓度及药代动力学研究[J], 张晓惠;王荣;谢华;尹强;李晓云;贾正平;张娟红;李文斌;4.反相离子对高效液相色谱法测定人血浆中阿昔洛韦浓度及药代动力学 [J], 赵飞浪;罗楠;袁倚盛5.反相高效液相色谱法测定犬血浆中左氧氟沙星浓度及其犬体内药代动力学 [J], 姜希凌;孙建国;王广基;李昊;李鹏;何卉因版权原因，仅展示原文概要，查看原文内容请购买。
HPLC法测定卡培他滨的含量及有关物质
HPLC法测定卡培他滨的含量及有关物质左家信;廖声华;严拯宇【期刊名称】《海峡药学》【年(卷),期】2013(025)001【摘要】目的建立高效液相色谱法测定卡培他滨含量及有关物质的方法.方法采用C18柱,以B(甲醇∶乙腈∶0.1%醋酸=7∶0.2∶12.8)-C(甲醇∶乙腈∶0.1%醋酸=16∶1∶3)为流动相,梯度洗脱,流速为1.0mL·min-1,进样量为10μL,检测波长为250nm,柱温为40℃,自动进样室为5℃.结果在浓度为0.0997～0.997mg·mL-1范围内线性关系良好(r=0.9999,n=6),检测限为0.020μg·mL-1.该方法能够分离卡培他滨及其有关物质.结论本方法灵敏、准确、专属性及重复性好,可用于卡培他滨的含量测定及有关物质限量检查.【总页数】4页(P48-51)【作者】左家信;廖声华;严拯宇【作者单位】中国药科大学分析化学教研室,南京,211198;国家药物质量与安全预警教育部重点实验室,南京,210009;中国药科大学分析化学教研室,南京,211198;国家药物质量与安全预警教育部重点实验室,南京,210009;中国药科大学分析化学教研室,南京,211198;国家药物质量与安全预警教育部重点实验室,南京,210009【正文语种】中文【中图分类】R927.2【相关文献】1.RP—HPLC法测定普伐他汀钠片含量,含量均匀度及其有关物质 [J], 林斌2.HPLC法测定贝林司他中有关物质的含量 [J], 孙朋杰;张莉;杜超;李伟;卓秋琪3.HPLC法测定苯丙氨酯原料药及片剂的含量和有关物质 [J], 王昕;王卫;唐素芳4.HPLC-ELSD法测定注射用阿奇霉素含量及有关物质 [J], 王殿奎;李婷;范桂强5.HPLC法测定盐酸莫索尼定片的含量、含量均匀度及原料的有关物质检查 [J], 李秀珍;姚华因版权原因，仅展示原文概要，查看原文内容请购买。
HPLC法测定妇科止痒胶囊中延胡索乙素的含量
HPLC法测定妇科止痒胶囊中延胡索乙素的含量黎德南;青涛;许振朝;杨桂芳;陈超凤;肖伟【期刊名称】《广西医学》【年(卷),期】2009(31)11【摘要】目的建立妇科止痒胶囊中延胡索乙素的含量测定方法.方法采用ODS C18色谱柱(250 mm×4.6 mm,5 μm),以甲醇-1%三乙胺溶液(磷酸调pH值至7.5)(60 ∶40)为流动相;流速:1.0 ml/min;检测波长:280 nm;柱温:30℃;外标法测定.结果延胡索乙素浓度在0.20～1.60 μg范围内线性关系良好(r=0.9999);平均回收率为99.38%(RSD=1.21).结论此方法简便、准确、重现性好,可作为妇科止痒胶囊中延胡索乙素的含量测定方法.【总页数】2页(P1700-1701)【作者】黎德南;青涛;许振朝;杨桂芳;陈超凤;肖伟【作者单位】广西南宁允上医药科技开发有限公司、南宁市工程技术研究中心,南宁市,530219;广西南宁市江南妇幼保健院,南宁市,530219;广西南宁允上医药科技开发有限公司、南宁市工程技术研究中心,南宁市,530219;广西南宁允上医药科技开发有限公司、南宁市工程技术研究中心,南宁市,530219;广西南宁允上医药科技开发有限公司、南宁市工程技术研究中心,南宁市,530219;广西南宁允上医药科技开发有限公司、南宁市工程技术研究中心,南宁市,530219【正文语种】中文【中图分类】R285.5【相关文献】1.RP-HPLC法测定消痛灵中延胡索乙素含量的方法研究 [J], 汪军;姚闽2.HPLC法测定益气养阴合剂中厚朴酚和厚朴酚和延胡索乙素的含量 [J], 刘传统;祁红3.RP-HPLC法测定傣药地不容中延胡索乙素的含量 [J], 卯明霞;陆应彩;姜明辉;彭霞4.RP-HPLC法测定创灼膏中延胡索乙素的含量 [J], 周春华;白冰;张颖;赵俞;马莉5.HPLC法测定肾石通颗粒（无糖型）中延胡索乙素的含量 [J], 孙奇因版权原因，仅展示原文概要，查看原文内容请购买。
反相高效液相色谱法测定注射用盐酸阿糖胞苷的有关物质
反相高效液相色谱法测定注射用盐酸阿糖胞苷的有关物质林焕泽;蓝忠;杨华;黄群【期刊名称】《中国药业》【年(卷),期】2009(018)015【摘要】目的建立测定注射用盐酸阿糖胞苷有关物质和降解产物的反相高效液相色谱(RP-HPLC)法.方法色谱柱为C18柱(250mm×4.6mm,5μm),以磷酸盐缓冲液(0.005 mol/L磷酸二氢钠和0.005 mol/L磷酸氢二钠)-甲醇(95:5)为流动相进行洗脱,流速为0.6 mL/min,检测波长为250 nm.结果主峰和各杂质峰均达到基线分离,理论塔板数按盐酸阿糖胞苷峰计算不低于3 000;盐酸阿糖胞苷、尿苷和阿糖尿苷的峰面积与质量浓度线性关系良好(n=5).结论所用方法灵敏、准确,适于注射用盐酸阿糖胞苷的有关物质测定.【总页数】2页(P27-28)【作者】林焕泽;蓝忠;杨华;黄群【作者单位】广东省茂名市人民医院,广东,茂名,525000;广东省茂名市人民医院,广东,茂名,525000;广东省茂名市人民医院,广东,茂名,525000;广东省茂名市人民医院,广东,茂名,525000【正文语种】中文【中图分类】R927.11;R979.1【相关文献】1.反相高效液相色谱法测定注射用卡络磺钠注射液的含量和有关物质 [J], 周水根;刘放2.反相高效液相色谱法测定注射用头孢米诺钠含量及其有关物质 [J], 封家福;张锦;代广会;周卿;景淑华;尚京川3.反相高效液相色谱法测定注射用辅酶Q_(10)冻干乳含量及有关物质 [J], 冯秀珍;姚瑶;丁燕飞;陶昱斐;张俊林4.反相高效液相色谱法测定盐酸苯乙双胍片中盐酸苯乙双胍及其有关物质双氰胺的含量 [J], 霍立茹;崔京;冯亚宁5.注射用苯唑西林钠利用反相高效液相色谱法测定其有关物质 [J], 李宝嫒因版权原因，仅展示原文概要，查看原文内容请购买。
转换波长高效液相色谱法同时测定复方咪康唑乳中乳酸依沙吖啶、曲安奈德和硝酸咪康唑的含量
转换波长高效液相色谱法同时测定复方咪康唑乳中乳酸依沙吖啶、曲安奈德和硝酸咪康唑的含量肖丽丽;崇岚;曾国生;罗美兰【期刊名称】《理化检验-化学分册》【年(卷),期】2018(054)012【摘要】称取复方咪康唑乳样品约1 g,加入乙醇25 mL,加热溶解后冷却,用乙醇定容至50 mL,摇匀,冷冻1 h后迅速用滤纸过滤,取续滤液放置至室温后,采用Agilent Eclipse Plus C18色谱柱(250 mm×4.6 mm,5μm)进行分离,以甲醇、乙腈和30 g·L-1乙酸铵溶液的混合液为流动相进行梯度洗脱,乳酸依沙吖啶、曲安奈德和硝酸咪康唑的检测波长分别为270,240,230 nm.乳酸依沙吖啶、曲安奈德和硝酸咪康唑的线性范围分别为40～180,40～200,800～401 mg·L-1,检出限(3S/N)分别为0.75,1.06,2.18 mg·L-1.方法用于测定复方咪康唑乳样品中的乳酸依沙吖啶、曲安奈德和硝酸咪康唑,测定值与标示值一致,加标回收率在96.1％～104％之间,测定值的相对标准偏差(n=6)小于1.0％.【总页数】4页(P1415-1418)【作者】肖丽丽;崇岚;曾国生;罗美兰【作者单位】江西省皮肤病专科医院,南昌 330001;南昌市食品药品稽查支队,南昌330038;江西省皮肤病专科医院,南昌 330001;江西省皮肤病专科医院,南昌330001【正文语种】中文【中图分类】O657.7【相关文献】1.RP-HPLC法同时测定复方曲安奈德乳膏中醋酸曲安奈德和硝酸咪康唑的含量 [J], 张咏梅2.高效液相色谱法测定复方咪康唑洗剂中硝酸咪康唑含量 [J], 杨瑾;莫国栋;曾维国;林丽3.高效液相色谱法测定复方硝酸咪康唑软膏中硝酸咪康唑和丙酸倍氯米松含量 [J], 罗荣;陈标4.反相高效液相色谱法测定曲咪新乳膏中醋酸曲安奈德和硝酸咪康唑的含量 [J],刘晓玲;梁晓东;崔杨;王婷婷;刘琳;丁银春;周化;范石虎5.反相高效液相色谱法测定曲咪新乳膏中硝酸咪康唑和醋酸曲安奈德的含量 [J],刘雁鸣;兰文因版权原因，仅展示原文概要，查看原文内容请购买。
HPLC法测定复方黄松洗液中蛇床子素的含量
HPLC法测定复方黄松洗液中蛇床子素的含量
檀时新;王小兵
【期刊名称】《中国医药导报》
【年(卷),期】2007(004)036
【摘要】目的:建立HPLC法测定复方黄松洗液中蛇床子素的含量.方法:采用SB-
C18分析柱(4.6 mm×250 mm,5μm);流动相:乙腈-水(65:35);检测波长:322 nm.结果:蛇床子素在0.053～1.060μg范围内线性关系良好(r=0.999 9),平均回收率为98.5%,RSD为3.6%.结论:本法操作简单、灵敏、准确,可用于复方黄松洗液的质量控制.
【总页数】2页(P163-164)
【作者】檀时新;王小兵
【作者单位】南京市中医院,江苏南京,210001;江苏省人民医院,江苏南京,210029【正文语种】中文
【中图分类】R917
【相关文献】
1.RP-HPLC法测定复方蛇床子搽剂中蛇床子素和醋酸地塞米松含量及方法验证 [J], 郑绍忠;王庆芬;张荣;黄艺蓉
2.RP-HPLC法测定气血双生合剂中淫羊藿苷、蛇床子素、五味子甲素与五味子乙
素的含量 [J], 马秀建
3.HPLC法测定复方黄松洗液中蛇床子素的含量 [J], 檀时新;王小兵
4.RP-HPLC法测定独活中蛇床子素和异欧前胡素含量 [J], 邢婕;胡晓静;赵春杰;宋
敏;李玲
5.HPLC法测定蛇床子中蛇床子素的含量 [J], 林进生
因版权原因，仅展示原文概要，查看原文内容请购买。
反相高效液相色谱法检测血浆中阿普唑仑浓度
反相高效液相色谱法检测血浆中阿普唑仑浓度
王丽嵘;张惠兰
【期刊名称】《中国药物与临床》
【年(卷),期】2005(005)003
【摘要】口服阿普唑仑药物的中毒，在临床较为少见，但阿普唑仑药物镇静作用较地西泮强，中毒危害较大，如果可及时检测阿普唑仑的血药浓度，将对临床治疗有一定的帮助。
【总页数】1页(P219)
【作者】王丽嵘;张惠兰
【作者单位】包头市第四医院药剂科,014030;包头市第四医院药剂科,014030【正文语种】中文
【中图分类】R9
【相关文献】
1.反相高效液相色谱法检测人血浆中双氯芬酸钠的浓度 [J], 胡爱萍
2.柱切换-荧光检测反相高效液相色谱法测定血浆中特布他林浓度 [J], 秦永平;邹远高;梁茂植;余勤
3.反相高效液相色谱法检测富含脂肪乳剂血浆中盐酸布比卡因浓度 [J], 王权光;陈丽梅;刘乐;陈莺;胡国新;徐旭仲
4.反相高效液相色谱法检测人血浆中双氯芬酸钠的浓度 [J], 胡爱萍;胡国新;邱相君
5.反相高效液相色谱法检测人血浆中罗红霉素浓度 [J], 王华;王刚;吴筱丹;朱亚尔因版权原因，仅展示原文概要，查看原文内容请购买。
HPLC对妥曲珠利纳米乳中有效成分含量的检测
HPLC对妥曲珠利纳米乳中有效成分含量的检测张志美;邓旭明;沈志强【期刊名称】《动物医学进展》【年(卷),期】2013(034)006【摘要】建立高效液相色谱法测定妥曲珠利纳米乳中妥曲珠利含量的方法.色谱柱为Agilent C18(4.6 mm×150mm,5μm)；流动相为磷酸二氢钾缓冲液(pH3):乙腈(45:55),流速1 mL/min,紫外检测波长240 nm,柱温30℃,进样量20 μL.结果表明,妥曲珠利含量在0.0625 μg/mL～100 μg/mL范围内与峰面积呈良好的线性关系,检测限为5 ng/mL,定量限为15 ng/mL,平均加样回收率为99.73％.试验表明,该方法简便灵敏,结果准确可靠,可用于妥曲珠利纳米乳中妥曲珠利的质量控制.【总页数】4页(P68-71)【作者】张志美;邓旭明;沈志强【作者单位】吉林大学畜牧兽医学院,吉林长春130062;山东省滨州畜牧兽医研究院,山东滨州256600;吉林大学畜牧兽医学院,吉林长春130062;山东省滨州畜牧兽医研究院,山东滨州256600【正文语种】中文【中图分类】S859.7【相关文献】1.妥曲珠利复合纳米胶束的制备 [J], 李锐;任丹丹;周建瑜;符华林;刘畅;申芸;凡国庆2.鸡肉冻干粉中妥曲珠利及妥曲珠利砜残留标准样品的研制 [J], 何平;鞠玲燕;崔嘉;李兆杰;宋晓华;杨丽君3.妥曲珠利纳米乳在鸡体内药代动力学研究 [J], 张志美;郭时金;付石军;王建军;徐倩倩;张颖;王艳萍;沈志强4.高效毛细管电泳法同时检测地克珠利和妥曲珠利的含量 [J], 施祖灏;陆俊贤;葛庆联;龚建森;刘学贤;祁克宗5.鸡组织中地克珠利和妥曲珠利残留HPLC检测方法的建立 [J], 施祖灏;朱良强;卢运站;祁克宗;彭开松因版权原因，仅展示原文概要，查看原文内容请购买。
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
===================================================================== Area Percent Report ===================================================================== Sorted By : Signal Multiplier: : 1.0000 Dilution: : 1.0000 Use Multiplier & Dilution Factor with ISTDs No peaks found ===================================================================== *** End of Report ***
===================================================================== Instrument 1 4/13/2017 9:36:30 AM WRH(HPLC-09) Page 1 of 1
VWD1 A, Wavelength=210 nm (D:\CHEM32\DATA\20170410\20170412 2017-04-12 12-27-26\008-1901.D) mAU 2500 2000 1500 1000 5.248 5.983 500 0 0 2 4 6 6.633 7.013 7.123 7.253 7.483 7.900 5.625
Data File D:\CHEM32\DATA\20170410\20170412 2017-04-12 12-27-26\001-1801.D Sample Name: BIZ2017-410-WJ8_0 ===================================================================== Acq. Operator : WRH(HPLC-09) Seq. Line : 18 Acq. Instrument : Instrument 1 Location : Vial 1 Injection Date : 4/12/2017 5:43:33 PM Inj : 1 Inj Volume : 5.000 µl Acq. Method : D:\CHEM32\DATA\20170410\20170412 2017-04-12 12-27-26\10-80A(210NM)BC.M Last changed : 2/15/2017 5:14:04 PM by LCY(HPLC-09) Analysis Method : D:\CHEM32\METHODS\RP-HPLC\BLHY-308_10 AD.M Last changed : 3/31/2017 4:40:26 PM by ZHT(HPLC-09) Catalog No : HY-18990 Batch#24239 A-RP-199 Additional Info : Peak(s) manually integrated
Instrument 1 4/13/2017 8:39:16 AM WRile D:\CHEM32\DATA\20170410\20170412 2017-04-12 12-27-26\008-1901.D Sample Name: BIZ2017-410-WJ8 ===================================================================== Acq. Operator : WRH(HPLC-09) Seq. Line : 19 Acq. Instrument : Instrument 1 Location : Vial 8 Injection Date : 4/12/2017 6:01:59 PM Inj : 1 Inj Volume : 5.000 µl Acq. Method : D:\CHEM32\DATA\20170410\20170412 2017-04-12 12-27-26\10-80A(210NM)BC.M Last changed : 2/15/2017 5:14:04 PM by LCY(HPLC-09) Analysis Method : D:\CHEM32\METHODS\RP-HPLC\BLHY-308_10 AD.M Last changed : 4/13/2017 9:36:01 AM by WRH(HPLC-09) (modified after loading) Catalog No : HY-18990 Batch#24239 A-RP-199 Additional Info : Peak(s) manually integrated
8
10
12
14
16
min
===================================================================== Area Percent Report ===================================================================== Sorted By : Signal Multiplier: : 1.0000 Dilution: : 1.0000 Use Multiplier & Dilution Factor with ISTDs Signal 1: VWD1 A, Wavelength=210 nm Peak RetTime Type Width Area Height Area # [min] [min] [mAU*s] [mAU] % ----|-------|----|-------|----------|----------|--------| 1 5.248 MM 0.0596 59.09393 16.51843 0.5429 2 5.625 MM 0.0651 1.06715e4 2731.70557 98.0476 3 5.983 MM 0.0745 10.28576 2.30250 0.0945 4 6.633 MM 0.0565 7.05663 2.08182 0.0648 5 7.013 MM 0.0520 10.64454 3.40895 0.0978 6 7.123 MM 0.0536 14.52176 4.51473 0.1334 7 7.253 MM 0.0633 12.76239 3.35806 0.1173 8 7.483 MM 0.0690 82.75723 19.99058 0.7604 9 7.900 MM 0.0559 15.37604 4.58452 0.1413 Totals : 1.08840e4 2788.46515